What is the optimal duration of neoadjuvant chemoimmunotherapy for resectable non-small cell lung cancer (NSCLC)?: a real-world study
Compared with 3 or more cycles, 2 cycles of neoadjuvant chemoimmunotherapy might achieve similar perioperative outcomes and long-term survival in selected patients. Prospective studies and extended follow-up are needed to verify the conclusions.
Authors
- Zhoujunyi Tian
- Jin Zhang (ORCID: https://orcid.org/0000-0001-7009-8865)
- Dong Liu (ORCID: https://orcid.org/0000-0001-5498-6352)
- Chaoyang Liang (ORCID: https://orcid.org/0000-0002-1469-6286)
- Zhenrong Zhang
- Haoshuai Yang
Institutions
- China-Japan Friendship Hospital (CN)
Publication Details
- Journal
- European Journal of Cardio-Thoracic Surgery
- Published
- 2025-07-01
- DOI
- https://doi.org/10.1093/ejcts/ezaf218
- Citations
- 1
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.52